Oriel Therapeutics Inc., Awarded Its First U.S. Patent
10/19/2005 5:10:23 PM
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--May 10, 2005--Oriel Therapeutics Inc., an emerging inhaled drug delivery company based in Research Triangle Park, announced today that it has been granted a United States Patent (6,889,690; issue date May 10th) for multi-dose dry powder drug packages for holding pharmaceutical grade formulations of inhalable dry powder substances.
The patent covers aspects of Oriel's multi-dose dry powder inhaler technology that provides a package to apply vibration directly to a powder drug as well as a design for delivery of drugs. The package can be configured to deliver drugs in combination without blending (i.e. in separate blisters). The vibration is individually tailored for a given drug product through use of powder physics principles and provides highly efficient dose delivery. Oriel's design enables increased formulation flexibility in the development of combination products. This coupled with the powder delivery technology will allow for more rapid product development and improved patient administration.
comments powered by